Vista Pharmaceuticals has paid GDUFA (Generic Drug User Fee Amendments of 2012) Facility fees payable by the company to US Food & Drug Administration (USFDA). GDUFA is a law designed to speed access to safe and effective generic drugs to the public, and reduce costs to industry.
Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1867.80 |
| Dr. Reddys Lab | 1301.30 |
| Cipla | 1433.10 |
| Zydus Lifesciences | 1112.10 |
| Lupin | 2356.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: